Dual-phase 18F-FDG PET can predict lung adenocarcinoma outcome

03/31/2010 | HealthImaging.com

A study involving patients with histologically confirmed lung adenocarcinoma found that the change in maximal standardized uptake values between early and delayed 18F-FDG PET can be a strong singular predictor of patient outcome and aid in patient management. "Patients with more than 25 percent increase in SUVmax had a median survival of 15 months, compared with 39 months for those with less than 25 percent increase in SUVmax," the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX